This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AB vs. CRON: Which Stock Is the Better Value Option?
by Zacks Equity Research
AB vs. CRON: Which Stock Is the Better Value Option?
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $15.80 in the latest trading session, marking a +0.13% move from the prior day.
Marijuana ETF Down 9% in Past Month: Time to Enter the Space?
by Sanghamitra Saha
Growing global acceptance, increasing legalization and beaten-down prices open up room for marijuana ETF investing.
New Strong Sell Stocks for April 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Cronos Group (CRON) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $17.69, marking a +0.71% move from the previous day.
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
Altria to Boost Interests in JUUL, Aims to Gain Voting Rights
by Zacks Equity Research
Altria (MO) provides information related to investment in JUUL to the FTC. It seeks to gain voting interests in JUUL.
Constellation Makes Big Cannabis Bet
by Daniel Laboe
Constellation Brands have been continuously adding to their stake in Canopy Growth (CGC), which is the leading player in the Canadian cannabis market. STZ just added another $4 billion investment in August bringing its total stake in Canopy to 38% ownership.
Short Sellers and Easing Rules Boost Pot ETF Higher
by Sweta Killa
Along with easing rules, short-selling of the stocks led to the spike in the pot ETF.
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher? (Revised)
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
New Strong Sell Stocks for April 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Cronos Group (CRON) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $18.61, marking a +0.98% move from the previous day.
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher?
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
New Strong Sell Stocks for April 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for March 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Buy Walgreens (WBA) Stock Ahead of Q2 Earnings, Before CBD Push?
by Benjamin Rains
Shares of Walgreens Boots Alliance, Inc. (WBA) have fallen roughly 9% this year, which stands in contrast to the market's nearly 13% climb and its industry's 4.5% average gains. But is it time to buy WBA stock ahead of earnings?
Marijuana ETF Outperforms in Q1: 6 Stocks Leading the Rally
by Sweta Killa
Though most of the stocks in the marijuana ETF portfolio delivered strong returns, a few were the real stars, soaring more than 60% in the first quarter.
US Marijuana Industry to Flourish in 2019: Who Gains?
by Nalak Das
Legalization has long been considered a boon for the marijuana industry.
Options Traders Expect Huge Moves in Cronos (CRON) Stock
by Zacks Equity Research
Investors need to pay close attention to Cronos (CRON) stock based on the movements in the options market lately.
Cronos Group (CRON) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $21.48 in the latest trading session, marking a -0.97% move from the prior day.
Altria (MO) Hurt by Low Cigarette Sales, Inclines Toward RRPs
by Zacks Equity Research
Altria (MO) is undertaking efforts to expand in the RRPs space amid receding cigarette shipping volumes.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $21.14, marking a -1.08% move from the previous day.
Altria Focuses on RRPs Growth, Closes Investment in Cronos
by Zacks Equity Research
Altria (MO) closes investment deal in Cronos Group. The move is in sync with the company's efforts to expand in the smokeless category.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.